Hormone Replacement Therapy Market Poised to Reach USD 46.32 Billion by 2034, Growing at 6.68% CAGR: Towards Healthcare Report

The hormonal replacement therapy market size is calculated at USD 25.88 billion in 2025 and is expected to reach around USD 46.32 billion by 2034, growing at a CAGR of 6.68% for the forecasted period.

Ottawa, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The global hormonal replacement therapy market size was valued at USD 24.26 billion in 2024 and is predicted to hit around USD 46.32 billion by 2034, rising at a 6.68% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.

Around the globe, a rise in various hormonal issues is boosting the widespread production of different hormones, which ultimately expands the global market.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5495

Key Takeaways

North America was dominant in the market in 2024.
Asia Pacific is expected to grow at the fastest CAGR during 2025-2034.
By product, the estrogen and progesterone replacement therapy segment dominated the market in 2024.
By product, the parathyroid hormone replacement therapy segment is expected to witness rapid expansion in the studied years.
By route of administration, the oral segment led the hormonal replacement therapy market in 2024.
By route of administration, the parenteral segment is expected to grow notably in the predicted timeframe.
By disease type, the menopause segment registered dominance in the market in 2024.
By disease type, the hypoparathyroidism segment is expected to grow at a significant CAGR during 2025-2034.

Market Overview & Potential

The global hormonal replacement therapy market supports replacing hormones during menopause, especially estrogen and sometimes progestogen, to resolve moderate-to-severe symptoms, such as hot flashes and bone loss. These therapies further also employed in detecting growth hormone deficiency in children and adults, and correcting thyroid disorders. The broader advances in wearable and implantable sensor technologies are focused on tracking hormone levels in real-time to determine the optimal time for starting therapy and for tailored treatment.

Key Metrics and Scope

Metric	Details
Market Size in 2024	USD 24.26 Billion
Projected Market Size in 2034	USD 46.32 Billion
CAGR (2025 - 2034)	6.68	%
Leading Region	North America
Market Segmentation	By Product, By Route of Administration, By Disease Type and By Region
Top Key Players	Eli Lilly and Company, Bayer AG, Noven Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Viatris, Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., ASCEND Therapeutics US, LLC. and AbbVie, Inc.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Significant Drivers Involved in the Market Expansion?

The worldwide accelerating instances of age-related hormonal deficiencies and conditions, including menopause and male hypogonadism, as well as lifestyle changes, stress, and environmental factors, are responsible for hormonal imbalances. These concerns are further expanding the adoption of well-developed hormonal replacement therapy. Alongside, a robust pipeline of new HRT products, like novel drug applications and approvals for different conditions, is supporting the overall hormonal replacement therapy market growth.

What are the Major Drifts in the Respective Market?

The escalating patient and doctor awareness of HRT advantages and other advancements are innovations in the bio-identical therapies.

In May 2025, London-based Hormona, a HealthTech company, raised a €7.8 million Seed round to drive its expansion and support the launch of its hormone tests.
In April 2025, HRT Club a leading pioneer of direct-to-consumer hormone replacement therapies, partnered with MyMenopauseRx, the premier online doctor's office, to enhance access to menopause care for women across 21 states.

What is the Arising Challenge in the Market?

In the hormonal replacement therapy market, there are specific developing adverse effects that are impacting its overall expansion, including blood clots, cardiovascular diseases, and few types of cancer, specifically in women undergoing treatment for menopause. The rising need for high expenses in HRT medications, doctor visits, and associated lab tests is also serving as a limitation in the wider adoption.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Regional Analysis

Why did North America Dominate the Market in 2024?

A substantial growth in the geriatric population is experiencing accelerated diagnoses of hormonal imbalances, like menopause and thyroid disorders, in North America is fueling the major demand for HRT approaches by 40% market share. Moreover, the US is widely developing implantable bioelectronic devices and wearable sensors, focused on tracking hormone levels in real-time, which will support in detecting the optimal window to start HRT and potentially even dispense hormones on demand. Researchers are working on testosterone for female sexual interest and non-hormonal alternatives, which are impacting the hormonal replacement therapy market expansion.

For instance,

In December 2024, Astellas Pharma US, Inc. and Dr. Jen Ashton partnered to introduce Cooler Moments to spotlight menopausal hot flashes and support women to advocate for themselves.

Download the single region market report @ https://www.towardshealthcare.com/checkout/5795

Asia Pacific Hormonal Replacement Therapy Market Trends:

During 2025-2034, the Asia Pacific is anticipated to witness a rapid growth in the hormonal replacement therapy market. This expansion is propelled by a rise in focus on women’s health and the aging population, mainly in China and India. Alongside, there are many progressing approaches, including innovative delivery systems, such as transdermal patches and nasal sprays, that are enhancing patient comfort and personalized treatment choices for a variety of needs. Recently, the 2025 APMF Consensus Statement facilitated updated guidance for healthcare professionals in the culturally varied Asia-Pacific region, superseding the previous 2008 statement.

Segmental Insights

By Product Analysis

How did the Estrogen and Progesterone Replacement Therapy Segment Lead the Market in 2024?

The estrogen and progesterone replacement therapy segment accounted for a major share of the hormonal replacement therapy market in 2024. This therapy plays a crucial role in osteoporosis, a condition common in postmenopausal women. They also possess wider application to manage symptoms, like hot flashes, night sweats, and mood swings. Ongoing developments, including transdermal estrogen delivery (patches, gels, creams), bypass liver metabolism, thus skipping the enhanced risk of blood clots seen with oral estrogen. Numerous research activities are showing estrogen therapies' advantages as an antidepressant.

On the other hand, the parathyroid hormone replacement therapy segment is predicted to expand at a rapid CAGR during 2025-2034. This kind of therapy has broader use in accelerating hypoparathyroidism and its associated conditions, such as osteoporosis cases. This therapy is highlighted application in PTH deficiency, which helps in preventing complications linked with conventional treatment, like hypercalciuria and ectopic calcification. Recently, new long-acting drug formulations like palopegteriparatide (TransCon PTH) have been approved to offer 24/7 stable PTH levels, optimizing calcium control, minimizing calcium-related complications, and improving quality of life.

By Route of Administration Analysis

Why did the Oral Segment Hold a Major Share of the Market in 2024?

In 2024, the oral segment registered dominance in the hormonal replacement therapy market. A wide range of demand for oral tablets and capsules is facilitating patient convenience, popularity, ease of administration, and inexpensiveness. The increasing prescription rate, bioidentical hormones, and extended-release options are supporting the wider adoption of oral therapies. In the last few years, the FDA has approved combined oral estrogens with selective estrogen receptor modulators (SERMs), including bazedoxifene, to omit the requirement for separate progestogen therapy in some women.

Whereas the parenteral segment is predicted to expand at a significant CAGR during 2025-2034. By-pass of liver metabolism and long-lasting effects of parenteral therapies, with reduced complications, like venous thromboembolism, are fueling the broader demand for this route. Also, transdermal patches offer maintenance of the estradiol-estrone ratio absorption, similar to a pre-menopausal state, which is advantageous for health and symptom management. Besides this, vaginal rings, gels, intrauterine systems (IUS), and subcutaneous implants facilitate a wide spectrum of choices for patients.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

By Disease Type Analysis

What Made the Menopause Segment Dominant in the Market in 2024?

In 2024, the menopause segment captured a major revenue share of the hormonal replacement therapy market. Along with the growing cases of menopause, the rising awareness of HRT as an efficient treatment for symptoms, such as hot flashes and mood changes, is also impacting the demand for HRT among women. Apart from this, continuous application of low and ultra-low doses of estrogen is suitable for treating menopausal symptoms and mitigating bone loss, with reduced side effects.

Although the hypoparathyroidism segment is anticipated to expand notably in the coming era. The growing instances of the condition, especially post-surgical hypoparathyroidism from thyroid surgeries, are boosting the advanced HRT. Nowadays, the world is aiming at more convenient, long-acting parathyroid hormone (PTH) analogs for accelerating calcium and phosphate homeostasis and patient quality of life, while resolving the burden of conventional calcium and vitamin D supplementation.

Browse More Insights of Towards Healthcare:

The topical antibiotic drug market reached a value of US$ 5.65 billion in 2024 and is expected to grow to US$ 5.95 billion in 2025, with projections suggesting it could hit US$ 9.59 billion by 2034, reflecting a CAGR of 5.45% over the forecast period.

The global marine pharmaceuticals market is estimated at US$ 6.19 billion in 2024, rising to US$ 6.52 billion in 2025, and is projected to reach US$ 10.34 billion by 2034, expanding at a CAGR of 5.29% between 2025 and 2034.

The GMP drug substance market was valued at US$ 2.55 billion in 2024, expected to grow to US$ 2.71 billion in 2025, and anticipated to reach US$ 4.64 billion by 2034, reflecting a CAGR of 6.14%.

The global berberine API market stood at US$ 523 million in 2024 and is projected to rise to US$ 556.74 million in 2025, with expectations to reach US$ 973.13 million by 2034, growing at a CAGR of 6.45% over the forecast period.

The AI-based pharmaceutical R&D services market is witnessing rapid growth, with revenues projected to reach several hundred million dollars by the end of the forecast period spanning 2025 to 2034.

The birth control pills market is also on a strong growth trajectory, expected to generate substantial revenue gains over the forecast period from 2025 to 2034.

The global meloxicam market was valued at US$ 7.62 billion in 2024, projected to increase to US$ 7.99 billion in 2025, and expected to surpass US$ 12.23 billion by 2034, growing steadily at a CAGR of 4.84%.

The global anti-aging market reached US$ 75.78 billion in 2024, projected to rise to US$ 79.97 billion in 2025, and expected to hit US$ 129.88 billion by 2034, showing a CAGR of 5.54%.

The global HIV PrEP market is poised for significant growth, with revenues expected to climb into the hundreds of millions between 2025 and 2034.

The global atopic drugs market is on an upward trajectory, projected to generate substantial revenue growth over the forecast period from 2025 to 2034.

Recent Developments

In July 2025, SynergenX, a national leader revolutionizing hormone therapy, TRT, weight loss, and wellness services, launched the SynergenX App to simplify hormone health management.
In April 2025, Spark Hormone Therapy, a player in bioidentical hormone replacement, unveiled its groundbreaking Auto Injector device, emphasizing the transformation of the at-home treatment experience by eliminating injection-related anxiety and discomfort.

Hormonal Replacement Therapy Market Key Players List

Eli Lilly and Company
Bayer AG
Noven Pharmaceuticals, Inc.
Pfizer Inc.
Merck & Co., Inc.
Viatris, Inc.
Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
ASCEND Therapeutics US, LLC.
AbbVie, Inc.

Download the Competitive Landscape market report @ https://www.towardshealthcare.com/checkout/5795

Segments Covered in The Report

By Product

Estrogen & Progesterone Replacement Therapy
HGH replacement therapy
Thyroid hormone replacement therapy
Testosterone Replacement Therapy
Parathyroid Hormone Replacement

By Route of Administration

Oral
Parenteral
Transdermal
Others

By Disease Type

Menopause
Hypothyroidism
Male hypogonadism
Growth hormone deficiency
Hypoparathyroidism

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5795

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.